周三，尽管制药公司礼来 (NYSE:LLY)第四季度收入未达市场预期，富国银行仍重申了其对礼来股票的"增持"评级和1,000.00美元的目标价。礼来报告的收入为135亿美元，低于约140亿美元的一致预期。

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

Up to 3.4 million eligible patients could benefit from the medication that treats type 2 diabetes and aids weight loss ...

在这个充满挑战的时代，糖尿病患者在生活中面临着许多困扰。而最近，一则令人振奋的消息从国家药监局传来：替西帕肽替尔泊肽（Mounjaro）在中国正式获批上市，经过重新命名为穆峰达，这可能意味着2型糖尿病患者的新生机。这款药物的独特设计和显著疗效正引发关注，成为医学界和患者心中的"希望之星"。 5月21日，国家药监局和礼来公司共同宣布，替尔泊肽注射液在中国的上市获批，这引起了不少人的注意。作为一种创新 ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

印第安纳波利斯 - 目前市值超过7,180亿美元，交易价格高于其 InvestingPro 公允价值的礼来公司（NYSE:LLY）今日宣布，预计2024年全年收入将达到约450亿美元，较上年显著增长32%。这家制药巨头保持着令人印象深刻的80.9%的毛利率，同时预测2025年收入将在580亿美元至610亿美元之间，显示出持续的增长势头。

Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

While talk show queen Oprah Winfrey has declined to name the brand she uses, she’s among the Hollywood stars who have been ...